Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.356
+0.004 (0.99%)
At close: Jan 17, 2025, 4:00 PM
0.347
-0.009 (-2.56%)
Pre-market: Jan 21, 2025, 8:19 AM EST
Cyclacel Pharmaceuticals Employees
Cyclacel Pharmaceuticals had 12 employees as of December 31, 2019. The number of employees decreased by 2 or -14.29% compared to the previous year.
Employees
12
Change (1Y)
-2
Growth (1Y)
-14.29%
Revenue / Employee
$6,167
Profits / Employee
-$1,123,417
Market Cap
2.24M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CYCC News
- 17 days ago - Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 6 weeks ago - Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire